Reference health
The pharmacology and therapeutic applications of monoclonal antibodies
59/59 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 59 checked references that resolve
resolves10.1002/eji.1830060713
Derivation of specific antibody‐producing tissue culture and tumor lines by cell fusion
resolves10.3109/07388551.2014.958978
Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy
resolves10.1080/21645515.2015.1074362
Research and development of therapeutic mAbs: An analysis based on pipeline projects
resolves10.1080/19420862.2015.1022692
An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions
resolves10.1007/s10072-010-0382-6
The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases
resolves10.3324/haematol.2008.001628
Anti-CD20 monoclonal antibodies: historical and future perspectives
resolves10.3389/fonc.2018.00086
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
resolves10.1038/nrc.2016.36
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
resolves10.1186/s40425-018-0316-z
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
resolves10.1016/j.ccell.2016.05.001
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
resolves10.1186/1741-7015-11-4
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
resolves10.1128/AAC.00110-19
Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection
resolves10.1128/JVI.00453-10
Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients
resolves10.1016/j.brainres.2013.08.035
Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn
resolves10.1517/17425247.2014.952627
Blood–brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody
resolves10.1080/19420862.2018.1465159
Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration
resolves10.1016/j.ab.2017.09.014
Glycan profiling of proteins using lectin binding by Surface Plasmon Resonance
resolves10.1016/j.molmet.2018.01.014
Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody
resolves10.4161/mabs.27658
Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
resolves10.1111/cts.12567
Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development
resolves10.1007/s13238-016-0323-0
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
resolves10.1016/j.drudis.2017.05.011
Advances in antibody–drug conjugates: A new era of targeted cancer therapy
resolves10.2165/11531280-000000000-00000
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
resolves10.4049/jimmunol.0903296
Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
resolves10.1124/jpet.117.244855
Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like Mice
resolves10.3109/07853890.2014.941919
Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials
resolves10.1007/s40264-015-0285-9
Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety
resolves10.1016/j.cellimm.2015.03.002
Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products
resolves10.1111/dme.12128
Real‐world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review
resolves10.1021/js970120d
Species Differences in Size Discrimination in the Paracellular Pathway Reflected by Oral Bioavailability of Poly(ethylene glycol) and d-Peptides
resolves10.1079/PNS19690007
The transmission of immune globulins from the mother to the foetal and newborn young
resolves10.1007/s11095-013-1212-3
Human and Non-Human Primate Intestinal FcRn Expression and Immunoglobulin G Transcytosis
resolves10.1023/A:1018853506830
Ontogenetic Development and Distribution of Antibody Transport and Fc Receptor mRNA Expression in Rat Intestine
resolves10.1152/ajpgi.00340.2012
Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice
resolves10.1046/j.1365-2567.1997.00326.x
Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells
resolves10.3389/fphar.2014.00225
The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups
resolves10.1002/prp2.218
FcRn binding is not sufficient for achieving systemic therapeutic levels of immunoglobulin G after oral delivery of enteric‐coated capsules in cynomolgus macaques
The 6 references without a DOI — listed, not checked
no DOI — not checkedPharmacology for chemists
no DOI — not checkedProQuest (Firm): A pharmacology primer theory, applications, and methods
no DOI — not checkedMonoclonal antibodies in cancer therapy
no DOI — not checkedTherapy of B‐cell lymphoma with anti‐CD20 antibodies can result in the loss of CD20 antigen expression
no DOI — not checkedMonoclonal antibodies for the treatment of cancer
no DOI — not checkedNewer agents in antiplatelet therapy: a review
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1002/prp2.535"><img src="https://citestamp.com/citestamped/10.1002/prp2.535/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1002/prp2.535)